Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2NBC7)

Drug Name

EZN-2968 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Hypoxia-inducible factor 1 alpha (HIF-1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[3]
IT-101	DMNDGWE	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
2-Methoxyestradiol	DMGBPME	Pulmonary arterial hypertension	BB01.0	Phase 2	[5]
PX-478	DM4AU8K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
ENMD-1198	DM9BJ3G	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Pyrrolidine carboxamide derivative 1	DMJK98Z	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hypoxia-inducible factor 1 alpha (HIF-1A)	TTQHWNA	HIF1A_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	2011 Pipeline of Santaris Pharma.
2	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
3	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
4	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
5	2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
6	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58.
7	ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
8	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.